Full-Time

Finance Lead

Forecasting

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$96.5k - $183.5k/yr

+ Short-term incentive program

Irvine, CA, USA

Hybrid

Three days in the office and two days remote per week; additional office days may be required.

Bachelor's

Category
Finance & Banking (1)
Required Skills
Power BI
Market Research
Inventory Management
Forecasting
SAP Products
Data Analysis
Excel/Numbers/Sheets
Financial Modeling

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A minimum of 6 years of combined experience in Commercial Finance, revenue forecasting, financial planning and analysis, cost accounting, auditing, and financial reporting is required.
  • A bachelor's degree in finance or accounting is required.
  • Strong financial, analytical, problem-solving, communication, and presentation skills are required.
  • Ability to think creatively and strategically, identify key issues, opportunities, and value drivers, and translate strategic insights into forecasts that drive business decisions.
  • Ability to understand market research and assess and quantify the financial impacts of marketing initiatives, promotional activities, and competitive events.
  • Ability to triangulate varied data sets and analytics to inform forecasting and solve business problems through proactive issue identification, data collection, analysis, and interpretation.
  • Ability to manage multiple tasks concurrently in a dynamic environment and produce high-quality, timely work.
  • Ability to gain alignment and partner effectively with cross-functional stakeholders across varying levels of management while influencing without direct authority.
  • Experience working in a dynamic business environment under tight timelines and quick turnarounds to achieve results and deliverables.
  • Solid understanding of SAP, BPC, Power BI, and Excel.
Responsibilities
  • Lead the demand and revenue forecasting process for US Fillers.
  • Lead the development and enhancement of forecasting models for US Fillers, ensuring deliverables align with timelines and strategic goals.
  • Craft clear narratives to support strategic decision-making in compliance with legal and corporate guidelines.
  • Identify key insights from data analysis, highlighting trends, opportunities, and risks.
  • Develop and drive solutions and strategies to enhance operational performance and address business issues.
  • Oversee the execution of Latest Best Estimates, Plan, Long-Range Plan, Average Daily Sales, and Sales and Operations Planning forecasts with Commercial, Finance, and Operations stakeholders.
  • Lead the monthly demand review by analyzing forecasting trends, forecast accuracy, and forecast proposals with Commercial and Global Operations stakeholders.
  • Prepare and submit Plan, Latest Best Estimates, Long-Range Plan, Average Daily Sales, and Sales and Operations Planning packages and supporting documentation for meeting reviews.
  • Develop realistic forecasts, monitor performance drivers, historical trends, and market dynamics, and use patient funnel, treatments, market size, market growth, market share, days-on-hand inventory, volume and stock-keeping-unit mix, and market events to improve forecast accuracy and predictability.
  • Apply technical expertise to refine forecasting models and support strategic business decisions.
  • Develop forecasts by analyzing performance drivers across customers and tiers and evaluating volume and stock-keeping-unit mix trends.
  • Collaborate with stakeholders to validate and integrate actuals into forecasting models while ensuring data integrity and accuracy.
  • Develop revenue targets for the sales force in coordination with the Incentive Compensation team.
  • Develop and submit royalty forecasts and royalty reporting packages in coordination with the Corporate team.
  • Develop and maintain financial forecasts and scenario models for upcoming assets to support launch planning, execution, revenue and investment analysis, business cases, promotional offers, profit-and-loss forecasts, profitability, return-on-investment analysis, and RCEs.
  • Compile reports and presentations that distill market dynamics and financial outcomes, and present sales results and future forecasts to Commercial with strategic context.
  • Prepare financial reports including sales roll-forwards, key opportunities and risks, and PPD schedules versus benchmarks with narratives and supporting documentation.
  • Prepare ad hoc financial analyses to support decision-making.
  • Engage with cross-functional teams to address business challenges and provide strategic financial insights and solutions.
  • Facilitate communication with management regarding forecast processes, issues, and strategic rationale.
  • Partner with Global Operations teams, including Brand Operations, Demand Planning, Supply Planning, and Sales and Operations Planning, to align supply and demand forecasts and optimize inventory, E&O, and cash flow.
  • Coordinate with Global Commercial Development and Marketing Analytics and Business Intelligence regarding competitor activities and market developments.
  • Serve as the US Fillers liaison for Gross-to-Net, Loyalty Programs, Field Force Operations, Incentive Compensation, and Customer Service teams.
  • Drive continuous process improvement by refining forecasting processes to improve data analysis efficiency and communication.
  • Collaborate on ad hoc analyses involving business performance issues and provide clear resolutions.
  • Prepare reports supporting earnings calls and external communications.
  • Support ad hoc requests, lead projects, and participate in corporate initiatives.
Desired Qualifications
  • Forecasting experience is preferred.
  • Prior pharmaceutical or consumer industry experience is preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.